Company news
Paradigm Biopharmaceuticals Ltd. news in 2026
Paradigm Biopharmaceuticals Ltd.'s news releases, calls and decks from 2026, newest first.
September 2026 Quarterly Activities Report & Appendix 4C
October 29, 2026
September 2026 Quarterly Activities Report & Appendix 4C
October 29, 2026
Convening Period Extended to 27 January 2027
October 28, 2026
Convening Period Extended to 27 January 2027
October 28, 2026
Deferral of AGM and Financial Reporting Obligations
October 22, 2026
Extension of Convening Period
October 22, 2026
Notification of cessation of securities - PAR
October 22, 2026
Further Agreed Convertible Note Redemption
October 22, 2026
Notification of cessation of securities - PAR
October 22, 2026
PPS Shows Significant Pain Benefit in Rest of World Analysis
October 15, 2026
PPS Shows Significant Pain Benefit in Rest of World Analysis
October 14, 2026
Expiry of PAROB Listed Options
October 12, 2026
Notification of cessation of securities - PAR
October 8, 2026
Update on Data Review and Convertible note redemption
October 8, 2026
Continuation of Suspension from Quotation
September 29, 2026
Appointment of Voluntary Administrators
September 29, 2026
Board Initiates Voluntary Administration
September 29, 2026
Continuation of Voluntary Suspension
September 27, 2026
Agreement to Return US$2M to Obsidian
September 24, 2026
Notification of cessation of securities - PAR
September 24, 2026
Phase 3 Interim Result Below Continuation Threshold
September 23, 2026
Suspension from Quotation
September 22, 2026
Trading Halt
September 20, 2026
Application for quotation of securities - PAR
September 17, 2026
Dr Daniel Furtner appointed Chief Medical Officer
September 14, 2026
Application for quotation of securities - PAR
September 14, 2026
Notice under Section 708A
September 10, 2026
Notification regarding unquoted securities - PAR
September 10, 2026
Drawdown of Tranche 4 under the Convertible Note Facility
September 10, 2026
Application for quotation of securities - PAR
September 10, 2026
Melbourne Investor Lunch
September 2, 2026
Appendix 4E and 2026 Annual Report
August 27, 2026
Appendix 4G and Corporate Governance Statement
August 27, 2026
Application for quotation of securities - PAR
August 25, 2026
80% Safety Review Complete, September IA on Track
August 12, 2026
Application for quotation of securities - PAR
July 30, 2026
June 2026 Quarterly Activities Report & Appendix 4C
July 29, 2026
Paradigm Receives $5.75m R&D Tax Incentive Refund
July 21, 2026
Drawdown of Tranche 4 under the Convertible Note Facility
July 12, 2026
PAR Completes Enrolment in Pivotal Phase 3
June 14, 2026
Results of Share Purchase Plan
May 31, 2026
DSMB 20% Review Supports Phase 3, Moldova Activated
April 29, 2026
March 2026 Quarterly Activities Report & Appendix 4C
April 27, 2026
Upsized $14M Placement Extends Runway Post IA
April 26, 2026
Paradigm Achieves 50% Patient Dosing in Phase 3
March 30, 2026
Appendix 4D and Half Year Report
February 26, 2026
Drawdown of Tranche 3 under the Convertible Note Facility
February 18, 2026
Published Canine Study Strengthens iPPS Phase 3 Rationale
February 10, 2026
Oral OA Animal Therapy Progresses via AVet Deal
February 8, 2026
December 2025 Quarterly Activities Report & Appendix 4C
January 29, 2026